BioPharm International-04-01-2020

BioPharm International

Critical Knowledge for Preparing Audits

April 02, 2020

Ask the Expert

33

4

Addressing data integrity, quality culture, aging facilities, investigations/corrective actions and preventive actions, and risk management is key when conducting audits, says Susan J. Schniepp, executive vice-president of post-approval pharma and distinguished fellow, Regulatory Compliance Associates.

What’s New in Downstream Technologies

April 01, 2020

Downstream Processing

33

4

The latest advances in downstream technologies include a fluid chromatography system, sensing and control units for hygienic valves, a compact valve platform, a membrane purification column, and a protein A affinity chromatography resin.

Benchtop Centrifuges

April 01, 2020

Product Spotlight

33

4

General Purpose Pro Centrifuge Series centrifuges by Thermo Fisher Scientific are designed to deliver a regulatory-compliant benchtop separation solution to meet the application needs of scientists working in biopharmaceuticals, academic research, and clinical diagnostic applications.

Chromatography Columns

April 01, 2020

Product Spotlight

33

4

Shim-pack Bio Diol and IEX columns from Shimadzu Scientific Instruments improve the accuracy of the characterization of peptides, oligonucleotides, and other biopharmaceuticals.

Biosimilars Poised for Gains in US Market

April 01, 2020

Regulatory Beat

33

4

FDA is encouraging alternative insulins and challenging anticompetitive practices.

BioPharm International, April 2020 Issue (PDF)

April 01, 2020

Issue PDF

33

4

Click the title above to open the BioPharm International April 2020 issue in an interactive PDF format.

Manufacturing APIs and the Supply Chain

April 01, 2020

Operations

33

4

Pharmaceutical Technology spoke with Jens Andersson, purchasing director at Cambrex Karlskoga, about the best way to ensure the security of the bio/pharmaceutical materials supply chain.

Biopharma’s Leadership Role in a Pandemic

April 01, 2020

From the Editor

33

4

As the coronavirus pandemic unfolds, the bio/pharma industry must practice science over hype.